Here's What Key Metrics Tell Us About Edgewell Personal (EPC) Q3 Earnings

Edgewell Personal Care (EPC) reported Q3 2025 results with revenue of $627.2 million, a 3.2% year-over-year decrease, missing the Zacks Consensus Estimate by 4.54%. Earnings per share (EPS) for the quarter were $0.92, down from $1.22 in the prior year and falling short of the $1.01 consensus estimate by 8.91%. Despite these financial misses, EPC shares have seen a 2% return over the past month, outperforming the S&P 500's 1% gain, and currently hold a Zacks Rank #2 (Buy).

Analysis

Edgewell Personal Care (EPC) reported weak financial results for its third quarter ending June 2025, missing analyst expectations on both revenue and earnings. Total revenue declined 3.2% year-over-year to $627.2 million, falling 4.54% short of the Zacks Consensus Estimate. Similarly, earnings per share came in at $0.92, a significant drop from $1.22 in the prior-year quarter and an 8.91% miss against the consensus estimate of $1.01. The underperformance was broad-based across its product segments, with Feminine Care sales declining sharply by 10.5% YoY and Sun and Skin Care sales falling 5.3% YoY, both missing analyst projections. The company's largest segment, Wet Shave, remained largely flat with a marginal 0.2% YoY sales increase but still failed to meet analyst estimates. In a notable contradiction to these poor fundamentals, EPC's stock has returned +2% over the past month, outperforming the S&P 500 composite's +1% gain, and it currently holds a Zacks Rank #2 (Buy), suggesting a potential for near-term outperformance despite the disappointing quarterly report.

Key Decisions for Investors

• Investors should exercise caution due to the significant miss on both revenue and EPS, driven by broad-based weakness across nearly all key product segments.
• The disconnect between the poor fundamental results and the stock's recent outperformance, along with its 'Buy' rating, warrants further investigation into whether the market is pricing in a future catalyst not reflected in this report.
• Closely monitor sales trends in the Feminine Care and Sun and Skin Care divisions in subsequent quarters, as a recovery in these segments is critical to reversing the negative operational performance.
• Given the flat performance in the core Wet Shave segment, investors should assess whether the company can reignite growth in its largest business line to support a long-term bullish thesis.